Off label FactorVII use

In this large administrative database analysis, the use of recombinant Factor VIIa use in US hospitals from 2000 to 2008 increased by 140 fold, 97% of which were off-label in 2008. It was most commonly utilized for CV surgery, ICH, and trauma patients. All cause mortality among patients receiving it was 27% (abstract). In addition, a systematic review found that the use of FactorVII in a variety of conditions did not improve mortality, and did increase arterial thromboses (abstract). Hospitals should evaluate their use of rFactorVII to determine costs, risks, and benefits

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment